Q4 2025 Management View CEO Brian Goff emphasized the company's 2026 strategic priorities, stating, "we're focused on executing a high-impact launch of AQVESME for the treatment of thalassemia in the ...
15h
DexCom outlines 2026 revenue growth of 11%-13% with G7 15 Day rollout and international expansion
DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results